A look at the GLP‐1 agonists

Abstract

A couple of years ago, I started exercising at home instead of going to the local Y. I'd typically have a television cable news channel on to keep me company, and was thereby subjected to abundant commercial advertising. Aside from marveling at the remarkably precise targeting of my demographic (old people), I pretty much managed to tune out the content. Recently, however, during more purposeful encounters with the media, I have found myself inundated with discussions of a specific product I had previously only associated with a strikingly annoying jingle: Ozempic.